Oncolytics Biotech Inc. (ONCY) - Earnings growth forecast for next year

Brandmark of Oncolytics Biotech Inc. (ONCY)

The forward-looking earnings per share growth forecast demonstrates the potential of Pelareorep, which activates immunity against tumors for Oncolytics Biotech Inc. (ONCY). The 22.20 level captures fresh values, reflecting synergy with pharma behemoths in the development of combination therapies. The brand's high authority within the scientific community is confirmed by the safety of viral platforms, making the trend of analyst expectations a key indicator for assessing the asset's value.

ONCY - Oncolytics Biotech, Inc. Projected earnings per share increase next year over the range 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for Oncolytics (ONCY)

- price and consensus price forecast:
Price Chart Oncolytics Biotech Inc.|ONCY - Price Target Chart
- market capitalization indicators:
Market Capitalization Oncolytics Biotech Inc.|ONCY - Enterprise Value
- book capitalization indicators:
Accounting Value per Share Oncolytics Biotech|ONCY - Total Net Assets|Market Capitalization to Book Value Ratio oncolyticsbiotech.com|ONCY - Total Asset Value of Company
- debt and liquidity details:
Debt to Equity Oncolytics Biotech Inc.|ONCY - Long-Term Liabilities to Capital|Short-Term Debt to Equity oncolyticsbiotech.com|ONCY - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Oncolytics|ONCY - Company Long-Term Liabilities|Company Short-Term Debt Oncolytics Biotech|Quick Liquidity oncolyticsbiotech.com
- earnings and market ratios statistics:
ONCY - Company Net Income|Expected Profit Oncolytics Biotech Inc.|ONCY - Price to Earnings Multiple|Forward P/E Multiple oncolyticsbiotech.com|ONCY - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oncolytics Biotech|ONCY - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Oncolytics Biotech|ONCY - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months oncolyticsbiotech.com|ONCY - Earnings per share growth rate in current year|Expected earnings per share growth for next year Oncolytics Biotech Inc.
- sales volume and revenue information:
ONCY - Company Total Sales|Projected Sales Volume Oncolytics Biotech|ONCY - Price-to-Revenue Coefficient|Forward P/S Multiple Oncolytics
Fundamental company valuation:ONCY, Oncolytics Biotech, Inc.
Core merchandise of Oncolytics Biotech, Inc.

This indicator measures the expected growth rate of earnings per share, reflecting the analysts' consensus forecast for future profitability. Assessing the EPS dynamics for the coming year determines whether the market is pricing in an increase in business efficiency. The metric is calculated as the percentage deviation of projected earnings from current values. For Oncolytics Biotech Inc. (ONCY), which depends on R&D funding and Phase II clinical trials, this trend signals the level of expert confidence in the commercialization of its drugs.

Analysis of competing companies

Net earnings per share growth forecast for next year Geron Corporation|Net earnings per share growth forecast for next year NBTX|Earnings growth forecast for next year BCYC|Earnings growth forecast for next year CytomX Therapeutics Inc (CTMX)|Perspective Therapeutics, Inc. - Expected earnings per share growth for next year|Projected earnings per share increase next year GNLX (Genelux Corp)|Molecular Partners AG - Earnings growth forecast for next year|Net earnings per share change forecast for next year LSTA|moleculin.com (MBRX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Galera (GRTX)|Net earnings per share growth forecast for next year Molecular Templates Corp